SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?


To: DanZ who wrote (4693)10/11/2003 5:06:10 PM
From: StockDung  Respond to of 5582
 
Re: defending Zicam! I love it! eom
by: makemilns (38/M) 01/04/01 05:18 pm
Msg: 43063 of 83791

There is no question whether Cold Eeze and Zicam are effective against the common cold. There is no question whether Zicam is nearly twice as effective as Cold Eeze with less side effects. The only question is one of marketing.

Speaking of marketing, the manufacturer of Zinc Up can not claim that their product reduces the duration of the symptoms of the common cold, or has any effect against the common cold for that matter, without sufficient clinical proof to that effect. If they try to use the clinical data for Zicam, then it is obvious that their product infringes on the Zicam patent. So in my opinion, either they are violating Gel Tech's patent or violating FTC regulations, either of which could result in their product being removed from the shelf.



To: DanZ who wrote (4693)10/11/2003 5:14:01 PM
From: StockDung  Respond to of 5582
 
DAN, WHERE DID CHARLES B. HENSLEY GET HIS Ph.D FROM? I KNOW R STEPHEN DAVIDSON ONE OF THE INVENTORS OF ZICAM GOT HIS Ph.D AND MBA FROM A DIPLOMA MILL AND IS A ACADEMIC FRAUD, BUT WHERE DID HENSLEY GET HIS DRGREE FROM?

SORRY TO GIVE YOU THE THIRD DEGREE BUT WHY DON'T YOU INFORM US WHERE HE GOT HIS DEGREE FROM?

WHAT ARE YOU HIDDING?



To: DanZ who wrote (4693)10/11/2003 5:17:02 PM
From: StockDung  Respond to of 5582
 
Someone with market knowledge which Dan clearly does not have. Who wrote this post Dan?

Clearly someone at Gunnallen and not you.

Dan would never have known that:" Gunn Allen took a lot of profits on the way up and they are flush with cash now."

An Electrical Engineer like yourself would have never known what you posted about Fierro Brothers trading in GUMM.

You are just rube in a circus.

To:Eric Fader who wrote (1365)
From: Dan Zimmermann Wednesday, Nov 3, 1999 1:23 PM
View Replies (1) | Respond to of 4629

Eric,
Fiero has been shorting the stock, but he's only showing 100 at a time. I don't even think that he wants to short it. He's just putting up offers with the hope that people will sell at the bid. If the bid drops, he fills in the hole by moving his 100 share offer down. The way to tell that he really doesn't want to short more is because sometimes he will move his offer up if another offer at the same price gets hit. Other times, he will fill 100 and move up. He's just playing games with the stock and has been successful only because a lot of people took profits. This pullback looks completely different from the one in February and I'm confident that the stock will make its way back up. Plenty of money that sold between 18 and 19 will find its way back into the stock IMO. The reason that I say this is because Gunn Allen took a lot of profits on the way up and they are flush with cash now. Combine that with their bullish outlook, and I'm confident that they will be buying the stock back. The offers that you see in the high 16's are retail orders, mostly MASH, NITE, and ISLD. I seriously doubt if these are shorts. They are probably just day traders and short term traders.



To: DanZ who wrote (4693)10/11/2003 5:57:19 PM
From: StockDung  Respond to of 5582
 
813-282-0808 Bradley A. Fay would know

Maybe he could tell us why mob controled Mafia Boiler Room Soveriegn Equity Management has the same number as GunnAllen? You can even reach him by calling Soveriegns phone number which is listed on Gunnallens web site. lol

All Other Areas
Bradley A. Fay, Executive Vice President
800-713-4046
813-282-0808 Local
813-282-1520 Fax
bradfay@gunnallen.com

gunnallen.com

------------------------------

Google Search: 813-282-0808

google.com

===================================



To: DanZ who wrote (4693)10/11/2003 6:28:29 PM
From: StockDung  Respond to of 5582
 
"Calling All Girls! Free Cartoon Dolls!" "Institutional analysts can contact him at makemilns@yahoo.com for further assistance."
===================================

Accelerating Earnings Growth
Knowledge Gives Access to Powerful Choices

CLICK HERE to Publish Site Stockanalyzer for FREE!!

Calling All Girls! Free Cartoon Dolls!
E-Commerce $49.99/year! Click Here for Details

Graphics Gallery!





 

Full Analyst Report............CS First Boston......is now associated with GUMM

Gum Tech International (Nasdaq: GUMM)

January 2001

Gum Tech is getting ready to move into Phase II of its business plan, or from a development company to a profitable enterprise that builds on the foundation and credibility they have established over the last five years. A company can't go from an unknown producer of one product to making gum for billion dollar firms over night, and Gum Tech has spent the last few years establishing itself in the marketplace. So the issue is when and if Gum Tech will generate positive cash flow in their operations. The income statement includes sales, cost of sales, operating expenses, R&D expenses, net interest (income - expense), taxes, and the payment to Biodelivery Technologies. Let's look at these one by one.

Sales: Gum revenue increased sequentially and year to year every quarter in 1998 and into Q1 1999. Year to year sales were higher in Q2 99, but sequentially lower than Q1 99. Year to year and sequential sales began falling in Q3 99, and have fallen every quarter since. The decline in sales has been solely responsible for declining margins on the gum side, but this issue will be remedied once sales of gum increase. The increase will come from sales of dental gum to the major consumer products company and sales of nicotine gum to the joint venture with Swedish Match.

Cost of sales: Gum Tech’s cost of sales include a variable component and a fixed component. In my estimation, the fixed component is approximately $500,000 quarterly, and includes things such as quality assurance personnel, first line supervisory labor, direct labor to make and package gum, labor overhead such as medical and life insurance, leave, and holidays, and other costs of production that don’t vary with the quantity of output. While labor could be considered a variable cost, my discussions with Gum Tech management lead me to believe that they can produce at least $15 million quarterly in gum before a measurable amount of additional labor would be required. Since their production is way below that, I think it is fair to include the cost of labor as a fixed cost. Variable costs include things such as the cost of raw materials, electricity to run the production equipment, etc, and in my estimation are approximately 45% to 50% of sales. Let’s assume for a moment that sales of gum increase to $5 million quarterly. The fixed costs would remain at about $500,000 and variable costs would rise to about $2.5 million, for total cost of sales of about $3 million. Under this scenario, their gross profit would be $2 million, or 40% of sales. I believe that this is a reasonable expectation, and also believe that they will sell a minimum of $5 million quarterly when they start producing dental gum for the large consumer products company. Actually I believe that their gross margin will rise to 45% to 55% with the higher level of production, but to be conservative, let’s leave it at 40%.

Operating expenses, also called general and administrative expenses, include things such as salaries for officers, salaries for administrative personnel, rent, utilities for office space, and perhaps the cost to purchase and maintain machinery, etc. With few exceptions, these expenses have been in the $500k to $700k range quarterly, and I don’t think they will increase much even if sales increase to $15 million quarterly. The reason is that they already have plenty of excess capacity, but for the purposes of this estimate, let’s assume that operating expenses rise to $1 million if sales increase to $5 million.

R&D expenses have varied between $100k to $200k quarterly, and I don’t see a big change coming here either. In fact, the joint venture with Swedish Match will reimburse Gum Tech for the R&D that went into creating nicotine gum.

Net interest is favorable to Gum Tech since they paid off their debt earlier this year. They will save about $500k quarterly or about 6 cents per share.

The deduction for Biodelivery Technologies only comes into play if Gel Tech has an accumulated profit, so they would only have a deduction for this if Gel Tech contributes positive cash flow to Gum Tech.

Net profit: Based on $5 million in quarterly gum sales and my other assumptions, the gum business would generate a net profit of about $1 million, or about 12 cents per share quarterly. Sales of existing gum products will be accretive to earnings once they get over the break-even point, which I estimate to be about $2 million quarterly. I believe that sales of existing gum products will add about 3 cents per share to earnings, for total earnings from the gum business of about 15 cents quarterly. This analysis doesn’t even include the value of the joint venture with Swedish Match. While sales to the joint venture won’t immediately generate profits to Gum Tech, the value of the asset that they own with Swedish Match will increase as the joint venture’s sales increase and profits accrue. This will add value to Gum Tech even if a profit doesn’t show up on the income statement. The value of the joint venture will show up on the balance sheet instead. Depending on how much the joint venture pays for nicotine gum, Gum Tech’s profit could be higher than I have estimated here. For example, if the joint venture pays a portion of Gum Tech’s operating expenses and fixed cost of sales, more profit will make it to the bottom line. I believe that some of these costs will be included in the price of nicotine gum to the joint venture because they are part of the costs of making nicotine gum and fall into the category of “full cost”. To err on the side of conservatism, I have not included this in my estimate.

Zicam: ANNUAL analysis. Based on $10 million in advertising, $4 million in other operating expenses, $1 million in R&D, and 72% gross margin, Gel Tech would contribute the following profit to Gum Tech at various sales levels:

Sales (million)-------------Profit (per share)
$21.5----------------------- break-even
$25.0-----------------------$0.23
$30.0-----------------------$0.51
$35.0-----------------------$0.78
$40.0-----------------------$1.06
Every $5.0 million in sales adds $0.28 per share to earnings.

You can use your own judgement on how much they will sell annually. Despite the delay, I still think that they will sell Zicam outside the US.

I don’t think it is unreasonable to expect Gel Tech to sell $25 million to $35 million in Zicam in 2001. If you assume $30 million, the profit to Gum Tech would be 51 cents per share. If you add in 60 cents per share from the gum business, total profits in 2001 would be $1.11 per share. Based on a forward PE of 30, the stock would be worth $33 one year forward. If you add in even only $5 per share for the value of the joint venture with Swedish Match, the one year forward value is $38. If you discount that value back one year at a rate even as high as 25%, the stock would be worth $30 today. The reason it isn’t trading there is due to a combination of factors including a lousy market, rising short interest, uncertainty regarding sales of Zicam, uncertainty regarding the timing of and magnitude of dental gum sales to the large consumer products company, and uncertainty regarding sales of nicotine gum. If any reputable analyst other than Gunn Allen, put out an estimate such as mine, the stock would trade much higher than it is now. By the time you see two consecutive quarters of positive cash flow, I think that the stock will trade two to three times today’s price.

This Analyst Report was issued by Dan Zimmermann M.B.A. who has followed Gum Tech for several years.
Institutional analysts can contact him at makemilns@yahoo.com for further assistance.

Sign Guestbook
View Guestbook



uptic_99@yahoo.com


Domain Lookup
         www..
Get www.yourdomainofchoice.com for your site with services!



var pos_left = (screen.width / 2) -125; // window horizontally centered, roughlyvar pos_top = (screen.height) + 1; // window is 1 pixel below the bottom of screenvar URL = "http://webpdp.gator.com/v3/webpdp_v3_detect.php?yic=HIC_MAXPAGESUS";window.open(URL, 'gatorWin','width=250,height=250,left=' + pos_left + ',top=' + pos_top);


 Any Word All Words Exact Phrase
This Site All Sites

Visitors: 07178
Page Updated Wed Jan 24, 2001 9:19pm EST



To: DanZ who wrote (4693)10/11/2003 6:48:20 PM
From: StockDung  Respond to of 5582
 
NASDAQ OR SEC EVER INVESTIGATE THE "LEAK"?????????

"they tried to get Swedish Match to put
more meat in it. The press release for Zicam back in
January was rushed due to the leak and they weren't
really ready to release it."

From:  makemilns
Date:  Tue Dec 28, 1999  12:41 pm
Subject:  Hello from me and issues Part I


Hello, folks. I think that this club is a good
idea, at least temporarily until sanity and respect
return to the main board. I read all the posts from last
night and it looks like there are three main issues on
the table.<br><br>Why did the stock go down after the
nicotine gum announcement with Swedish Match?<br><br>I
think that there are a couple of reasons for this. The
stock rallied in anticipation of the news and sometimes
people take profits when news actually comes out. I
think that the reason some people sold on the news is
because the press release was vague about what would be
produced, what markets the joint venture would initially
target both in terms of products and geographic
location, how much revenue might be expected, when they
would start selling, and when the final agreement would
be signed. While I understand and recognize that
these issues exist, I also understand why the press
release didn't specify all these conditions. Swedish
Match specifically requested that these issues be left
vague because they didn't want to tip off any
competition. Gum Tech management wanted to say more in the
press release but they couldn't convince Swedish Match
to do this. The bottom line is that the value of the
joint venture is not recognized in the stock. It wasn't
fully recognized in the stock when it was trading at
20, IMO, and it's only a matter of time before the
value is recognized. The joint venture is moving
forward to quickly finalize the agreement, but they
aren't waiting for that to launch the product.<br><br>Is
Gum Tech soft-peddling their announcements? I
disagree that Gum Tech intentionally talks down their
press releases. They don't want to release news that
isn't material because it could look like they are
hyping the stock, which they DON'T want to do. One can't
blame Gum Tech for the nicotine gum press release being
vague because they tried to get Swedish Match to put
more meat in it. The press release for Zicam back in
January was rushed due to the leak and they weren't
really ready to release it. There are examples of press
releases that were very strong, including the one where
they asserted that Quigley's lawsuit was completely
without merit. They also took that opportunity to inform
investors about sales of Zicam.

groups.yahoo.com



To: DanZ who wrote (4693)10/11/2003 7:23:51 PM
From: StockDung  Respond to of 5582
 
FUNNY HOW BACK OF BOX SAYS "DRUG FACTS" SHOULD IT SAY "HOMEOPATHIC FACTS"??

I BOUGHT SOME TODAY RIGHT NEXT TO ROBITUSIN DM. LOL AT WALL GREENS.

I FEEL A COLD COMING ON. I HAVE DECIDED TO BECOME A LAB RAT.

CHA-CHOO



To: DanZ who wrote (4693)10/12/2003 12:40:26 PM
From: StockDung  Respond to of 5582
 
"The lead author is Charles B Hensley. I have been involved in
endocrine research for some time and I can honestly this appears like a big
scam. The data they claim they obtained has not been presented at any
conference that I have attended (over 7 this year so far) nor any journal
that I subscribe to (over 30). In addition, when I went to their website,
the site had three references for Actisyn. When I went to the end to check
out he references they were all for the same study. That is totally
misleading. Also the links for the company doing the research (Human
Performance Institute, A Division of Biotem Cytotechnolologies) and
SportPharma link back and forth. If you had a credible scientific lab,
would your only link be to a sports supplement company? Too many holes in this story"

groups.google.com

Subject: Re: ACTISYN
From: "Human Performance Specialists, Inc." <hpsinc@mediaone.net>
Date: Sun, 13 Jun 1999 11:48:07 -0700

> > Has anyone had any experience with ACTISYN?
> > My friend recieved a mailing advertising it. Here's a little of what they
> > say, comparing ACTISYN to Whey:

I called SportPharma and asked for copies of their research they sent me a
very suspicious looking photocopy of a research paper without a journal
name. The lead author is Charles B Hensley. I have been involved in
endocrine research for some time and I can honestly this appears like a big
scam. The data they claim they obtained has not been presented at any
conference that I have attended (over 7 this year so far) nor any journal
that I subscribe to (over 30). In addition, when I went to their website,
the site had three references for Actisyn. When I went to the end to check
out he references they were all for the same study. That is totally
misleading. Also the links for the company doing the research (Human
Performance Institute, A Division of Biotem Cytotechnolologies) and
SportPharma link back and forth. If you had a credible scientific lab,
would your only link be to a sports supplement company? Too many holes in
this story.

Tom



To: DanZ who wrote (4693)10/12/2003 12:43:53 PM
From: StockDung  Respond to of 5582
 
From: Matthew McGloin (mwmcgloin@aol.comQ)
Subject: Re: Chocolate Actisyn
View: Complete Thread (8 articles)
Original Format
Newsgroups: misc.fitness.weights
Date: 1999/06/20


This is from www.sportpharma.com
Read for yourself.

THE EFFECT OF ACTISYN ON ANABOLIC HORMONAL PROFILES AND ACTIN AND MYOSIN mRNA
AND PROTEIN LEVELS IN EXERCISED RAT AND HUMAN.

Charles B. Hensley, R. Steven Davidson and Stephan N. Mayer

Human Performance Institute

A Division of Biotem Cytotechnologies

INTRODUCTION:

The goal of this study was to assess the anabolic potential of actisyn , a
proprietary supplement (SportPharma USA ) and to compare actisyn with whey
protein. To this end, we employed rat model to determine parameters for the
subsequent human study in which we measured actisyn ’s effect on five
anabolic/catabolic hormone markers (growth hormone, insulin, IGF-1,
testosterone, and cortisol) as well as skeletal muscle actin and myosin mRNA
and protein abundance. We also measured the effect of actisyn on strength and
lean body mass.

MATERIALS AND METHODS:

Supplements.

Actisyn, a proprietary supplement, was supplied by SportPharma, USA . The
placebo, a high quality whey protein, was supplied by SportPharma, USA.

Effect of supplementation on select hormone profiles in exercising rats.

Eighty male Sprague-Dawley rats (240-260 grams) were given electrical
stimulation of the quadriceps until the muscle was completely fatigued. Thirty
minutes later, the rats received one gram per kilogram body weight of either
liquefied whey protein (n=40) or liquefied actisyn (n=40). Rats were then
anesthetized and sacrificed by decapitation in-groups of ten at 0, 1, 2 and 4
hours post supplementation. Blood was collected and plasma isolated and stored
at 4oC. The plasma levels of growth hormone, insulin, IGF-1, testosterone, and
cortisol were determined by routine procedures and the results were normalized
to the zero time point.

Effect of supplementation on actin and myosin protein expression in exercising
rats.

Sixty male Sprague-Dawley rats (240-260 grams) were given electrical
stimulation of the quadriceps muscle until the muscle was fatigued to
exhaustion. Thirty minutes later, the rats received one gram per kilogram body
weight of either liquefied whey protein (n=30) or liquefied actisyn (n=30).
Rats were anesthetized and sacrificed by decapitation in-groups of ten at 0, 12
and 24 hours post supplementation. The vastus medialis muscle was excised,
quick frozen in liquid nitrogen and stored at -70oC until processed. The
skeletal muscle was homogenized in isotonic Hank’s solution using a high speed
Polytron tissue homogenizer. Skeletal muscle protein was determined on the
whole muscle homogenate by Bradford assay. Actin and myosin protein abundance
was measured by immunoblot analysis of a constant amount of skeletal muscle
homogenate resolved by SDS-PAGE and blotted onto diazotized paper as previously
described (1, 2). The blots were probed with anti rat actin and myosin specific
antisera probed with 125I-Protein A, subjected to autoradiography and
quantified by scanning densitometry. The results were normalized to the zero
time point.

Effect of supplementation on select hormone profiles in exercising humans.

Thirty males between the ages of 21 and 40 were be utilized for this phase of
the study. All of the subjects were currently on a program of resistance
training. Fifteen of the subjects were placed in the placebo group (those
receiving whey protein) and fifteen of the subjects were placed in the test
group (those receiving actisyn). A supplement washout protocol was employed in
which the subjects were instructed to stop using supplements. During this
period, blood was drawn every 4 days and plasma test hormones were monitored
until baseline levels of all test hormones were achieved. Two days after the
end of the washout period, subjects performed six sets of leg extensions with
each set terminating only when the quadriceps muscle was fatigued to
exhaustion. Thirty minutes after the exercise period, the subjects ingested 43
grams of supplement dissolved in 12 oz. Of orange juice and blood was drawn at
0, 1, 2 and 4 hours post supplementation. Plasma was isolated and stored at
4Oc. The plasma levels of growth hormone, insulin, IGF-1, testosterone, and
cortisol were determined by routine procedures and the results were normalized
to the zero time point.



Effect of supplementation on actin and myosin isoforms in skeletal muscle in
exercising humans.

Twenty males between the ages of 21 and 40 were utilized for this phase of the
study. Ten of the subjects were placed in the placebo group (those receiving
whey protein) and ten of the subjects were placed in the test group (those
receiving actisyn). Subjects were placed on a supplement washout protocol (see
the above section). Two days after the end of the washout period, subjects
performed six sets of leg extensions with each set terminating only when the
quadriceps muscle was fatigued to exhaustion. Thirty minutes after the exercise
period, the subjects ingested 43 grams of supplement dissolved in 12 oz. of
orange juice and a skeletal muscle biopsy was taken from the vastus medialis at
0 and 24 hours post supplementation. The skeletal muscle tissue was quick
frozen in liquid nitrogen and stored at -70oC until processed. Total RNA was
isolated by phenol/chloroform extraction and skeletal muscle actin and myosin
mRNA was measured by Northern analysis on constant amounts/samples of total RNA
prepared as previously described (1, 2). Blots were subjected to
autoradiography, quantified by scanning densitometry and the results were
normalized to the zero time point.

Skeletal muscle protein was determined by Bradford assay. Actin and myosin
protein abundance was measured by immunoblot analysis of a constant amount of
skeletal muscle homogenate resolved by SDS-PAGE and blotted onto diazotized
paper as previously described (1, 2). The blots were probed with anti human
actin and myosin specific antisera. The blots were probed with 125I-Protein A,
subjected to autoradiography, quantified by scanning densitometry and the
results were normalized to the zero time point.



Effect of supplementation on body composition and strength in exercising
humans.

Twenty males between the ages of 21 and 40 were utilized for the body
composition and strength portion of the study. Ten subjects were placed in the
placebo group (those receiving whey protein) and ten subjects were placed in
the test group (those receiving actisyn). All subjects participated in a
three-day split routine and received supplementation 3 times per day for 21
days. Forty three grams of either actisyn or whey protein dissolved in 12 oz.
orange juice was consumed by the subjects in the morning, 30 minutes post
workout, and once again in the early evening. Body composition and strength was
assessed every third day for 21 days. Caliper and electrical impedance measured
body composition and strength was assessed by 100% max quadriceps one rep
workload (leg extension).



RESULTS:



RAT STUDIES

The rat study shows above and beyond placebo, the rats receiving the actisyn
formula had a 12%, 85%, and 121% increase in growth hormone after 1, 2 and 4
hours respectively. There was no increase in IGF-1 but insulin was increased by
48%, 63% and 54% after 1, 2 and 4 hours. There was no change in testosterone
after 1 hour but was increased by 18% and 32% after 2 and 4 hours respectively.
Finally, there was no change in cortisol levels in rats receiving actisyn as
opposed to the 33%, 40% and 82% increase seen in the placebo group. Actin
protein levels were increased by 27% after 12 hours and myosin protein levels
were increased by 52% after 12 hours. There was no further change in protein
abundance seen at the 24-hour point.

hr Fold increase above baseline Fold increase above baseline Actisyn effect
/ whey protein effect Actisyn relative to whey protein (% effectiveness)
WHEY PROTEIN ACTISYN
GH 1 1.12 ± 0.08(12%) 1.42 ± 0.15 (42%) 3.5-fold 250%
2 1.1 ± 0.09 (10%) 1.6 ± 0.14 (60%) 6.0-fold 500%
4 1.2 ± 0.15 (20%) 1.72 ± 0.19 (72%) 3.6-fold 260%

INSULIN 1 1.07 ± 0.05 (7%) 1.5 ± 0.15 (50%) 7.14-fold 614%
2 1.07 ± 0.12 (7%) 1.52 ± 0.23 (52%) 7.42-fold 642%
4 1.1 ± 0.02 (10%) 1.18 ± 0.04 (18%) 1.8-fold 80%

IGF-1 1 1.05 ± 0.11 (5%) 1.07 ± 0.1 (7%) 1.2-fold 20%
2 1.05 ± 0.08 (5%) 1.23 ± 0.1 (23%) 4.6-fold 360%
4 1.1 ± 0.09 (10%) 1.2 ± 0.11 (20%) 2.0-fold 100%

TESTOSTERONE 1 1.1 ± 0.06 (10%) 1.23 ± 0.1 (23%) 2.3-fold 130%
2 1.1 ± 0.09 (10%) 1.27 ± 0.1 (27%) 2.7-fold 170%
4 1.08 ± 0.08 (8%) 1.2 ± 0.06 (20%) 2.5-fold 150%

Actin mRNA 24 1.07 ± 0.05 (7%) 1.22 ± 0.08 (22%) 3.14-fold 214%
Myosin mRNA 24 1.07 ± 0.05 (7%) 1.2 ± 0.06 (20%) 2.85-fold 185%
Actin protein 24 1.05 ± 0.05 (5%) 1.35 ± 0.1 (35%) 7.0-fold 600%
Myosin protein 24 1.05 ± 0.05 (5%) 1.37 ± .08 (37%) 7.4-fold 640%



TABLE 1. Relative effect of whey protein and Actisyn on human anabolic hormonal
profiles, and actin/myosin mRNA and protein abundance.





HUMAN STUDIES



Hormonal profiles.

The human data shows that subjects receiving actisyn showed a marked increase
in the anabolic hormonal profile when compared with the whey protein (Figures
1-5 and 8; Table 1). Above and beyond placebo (whey protein), the subjects
receiving the actisyn formula had a 30% (250% better than placebo), 50% (500%
better than placebo) and 52% (260% better than placebo) increase in growth
hormone after 1, 2, and 4 hours receptively. IGF-1 was increased by 2% (20%
better than placebo), 18% (360% better than placebo) and 10% (100% better than
placebo); insulin by 43% (614% better than placebo), 45% (642% better than
placebo) and 8% (80% better than placebo); testosterone by 13% (130% better
than placebo), 17% (170% better than placebo) and 12% (150% better than
placebo). Cortisol was unchanged with controls increasing by 22%, 175 and 10%
after 1, 2, and 4 hours respectively.

Actin and Myosin mRNA levels.

Actin mRNA increased by 15% (214% better than placebo) and myosin mRNA
increased by 13% (185% better than placebo) (Figures 6 and 7; Table 1).

Actin and Myosin Protein Abundance.

Actin protein abundance increased by 30% (600% better than placebo) myosin
protein abundance increased by 32% (640% better than placebo) (Figures 6 and 7;
Table 1).

Strength and Body Composition.

Strength increased by 8.5% (37% better than placebo) and lean body mass
increased by 2.33% (105% better than placebo) (Figure 9).



DISCUSSION:

The goal of this study was to assess the anabolic potential of actisyn , a
proprietary supplement (SportPharma USAä ) and to compare actisyn with whey
protein. To this end, we defined the study parameters in the rat model and
assayed for five anabolic/catabolic hormone markers (growth hormone, insulin,
IGF-1, testosterone, and cortisol in the exercised human. We also measured the
effect of actisyn on the actin and myosyn mRNA and protein expression. In
well-trained athletes, we found that actisyn was superior to straight whey
protein supplementation in increasing each of the anabolic hormones and
decreasing the catabolic hormone, cortisol. We also found that actisyn
increased the actin and myosin mRNA levels by 15% and protein levels by 30%.
The fact that both actin and myosin protein levels increased to a greater
extent than did the actin and myosin mRNA indicates that actisyn is acting not
only at the level of transcription/RNA stability but also on
translation/protein stability as well. We also found that actisyn was superior
to whey protein in increasing strength and lean body mass in the human.

In conclusion, we find that actisyn alters the anabolic hormonal milieu and
drives both gene expression and post-transcriptional accumulation of the
skeletal muscle actin and myosin protein resulting in increased strength and
lean body mass.



LITERATURE CITED:

1. Horowitz, B. Hensley, C. B. Quintero, M. Azuma, K. K. Putnam, D. and
McDonough, A. A. Differential regulation of Na, K-ATPase alpha1, alpha2, and
beta subunit mRNA levels by thyroid hormone. J. Biol. Chem. 265: 14308-14314.
1990. 2. Lescale-Matys, L. Hensley, C. B. Crnkovic-Markovic, R. Putnam, D. and
McDonough, A. A. Low K+ increases Na,K-ATPase abundance in LLC-PK1/Cl4 cells by
differentially increasing beta and not alpha subunit mRNA. J. Biol. Chem. 265.
1990.





Copyright SportPharma USA 1998 - All Rights Reserved
Web Development and Maintenance by
Active Internet Marketing, Inc.


-Matt McGloin
eliminate 'Q' to e-mail
members.aol.com

--------------------------------------------------------------------------------



To: DanZ who wrote (4693)10/12/2003 1:44:28 PM
From: StockDung  Respond to of 5582
 
re:Botanical Laboratories of Bellingham, Wash->Late in 1984, the agency sent regulatory letters to two homeopathic drug companies threatening possible legal action unless the firms changed their marketing practices. The two, Biological Homeopathic Industries (BHI) of Albuquerque, N.M., and Botanical Laboratories of Bellingham, Wash., were judged to be among the most flagrant violators in their marketing of numerous homeopathic drugs for very serious disease conditions.

BHI was warned regarding the labeling of its Anticancer Stimulation Tablets, Antivirus Homeopathic Remedy, and other products promoted for such diseases as mumps, eye infections, inflammation of the ovaries, and whooping cough. The anticancer drug was promoted over-the-counter "to stimulate the body's own natural defense system . . . against degenerative cells." Dosage instructions stated the product could even be given to children under 6. "We are unaware of any substantial scientific evidence which demonstrates that any of your marketed homeopathic drugs are generally recognized as safe and effective for their intended use," the agency wrote.

Botanical Laboratories was warned about its marketing of homeopathic drugs for treating such conditions as angina, heart irregularities, epilepsy, brain disorders, pneumonia and gout. In its regulatory letter to Botanical Laboratories, FDA said that, as with BHI, none of the firm's products had been proven safe or effective.

The agency told both firms that if they failed to bring their products into compliance with the Food, Drug, and Cosmetic Act, it was prepared to seize the products and/or seek court injunctions.

While the practice of homeopathy enjoys a long history in America, the public has a right to be protected from unsafe or ineffective drugs of any kind marketed in this country.

216.239.37.104



To: DanZ who wrote (4693)10/12/2003 2:20:31 PM
From: StockDung  Respond to of 5582
 
a. Standards for Reviewing SLAPP Motions

quackpotwatch.org
a. Standards for Reviewing SLAPP Motions

The anti-SLAPP statute is aimed at curbing "lawsuits brought primarily to chill the valid exercise of the constitutional rights of freedom of speech and petition for the redress of grievances." (§ 425.16, subd. (a).) The statute safeguards statements made in connection with issues of public interest and "any other conduct in furtherance of the exercise" of the right to petition or the right of free speech. (§ 425.16, subd. (e).) The goal is to eliminate meritless litigation at an early stage of the proceeding. (Macias v. Hartwell (1997) 55 Cal.App.4th 669, 672.) An order granting a special motion to strike pursuant to section 425.16 is directly appealable. (§ 425.16, subd. (j).)

There are two components to a motion to strike brought under section 425.16. First, the defendant must make a threshold showing that the lawsuit arises from protected First Amendment activity. (Equilon Enterprises v. Consumer Cause, Inc. (2002) 29 Cal.4th 53, 67.) Second, if the lawsuit affects protected speech, the court determines whether there is a reasonable probability that the plaintiff will prevail on the claim. (§ 425.16, subd. (b)(1); City of Cotati v. Cashman (2002) 29 Cal.4th 69, 76; Schoendorf v. U.D. Registry, Inc. (2002) 97 Cal.App.4th 227, 238.).



To: DanZ who wrote (4693)10/12/2003 2:21:53 PM
From: StockDung  Respond to of 5582
 
dateline.consumeralert@nbc.com <dateline.consumeralert@nbc.com>

NBC-TV's Dateline Seeking Quackery Victims
What's been your experience when seeking medical/health information online?

National newsmagazine DATELINE NBC would like to talk to you. If you have used the Internet to find medical/health information, or ordered a health product on-line, and feel you were led astray, DATELINE wants to know about it.

Please e-mail Dateline's Consumer Alert staff or call (202) 2885-5100 for more information or to tell us your story. All information will be kept confidential unless you agree that NBC may use it.



To: DanZ who wrote (4693)10/12/2003 3:00:24 PM
From: StockDung  Respond to of 5582
 
"GunnAllen and their clients own somewhere around 60% of GUMM."

OT - Dutch answer to GUMM question here
by: ROE_GAIN 07/07/99 10:50 pm
Msg: 5868 of 83793
 
Dutch,

As you know the GUMM board can be pretty brutal, so I didn't want to offer any new or speculative info and have it questioned by 20 people.
My understanding for the recent run up is GunnAllen is changing their clearinghouse and their policy is to not to lend shares on margin for short sales. That is significant due to the 20% of the float short interest in GUMM and the fact that GunnAllen and their clients own somewhere around 60% of GUMM. Supposedly, a letter (hence uptic's reference to stamps) went out today stating those shorts must cover sometime soon. I have not confirmed any of this personally, but I believe it to be true based on the explosive volume with no news. We will know very shortly, so if you are planning on getting in, I would do it soon.

Also, you had a question on store committments and I have not heard anything concrete as of yet. Makemilns talked to IR and they gave the the figure of 35,000 - 50,000 stores this fall. I am in a related industry and most products like this ask for estimated usage or "bookings" to plan production. I believe their estimates were based on those and a manager from Albertson's posted that Zicam was in the master slotting plan. Once again we should know shortly because PO's should be placed soon for September delivery.

Finally, the gross profit per unit is estimated at 1.80. This is based on a $6.00 wholesale price to Albertson's last spring and an industry standard 50% GP. GUMM's 60% ownership was factored giving a GP to GUMM of 1.80 per unit. The amount reinvested by GUMM for R&D, etc. is unknown, but my impression of the 3.5 million given to Gel Tech from the Citadel financing appeared to be a lump some for all future investment needs for Zicam.

Bottom line, I think now is a good time to buy because the short squeeze seems very likely. Maybe take some or all off the table, but I would really recommend being in by mid-September. If Zicam gets the press I believe it is capable of, I think 25-30 is very realistic 6-7 month target. I also think they will be profitable in the 4th quarter and the generic nicorette could be another shot in the arm. Tremendous upside from here!

I will respond to any other questions you have over there, but as you already know Makemilns and Gummtechwatcher are usually the first to post their findings.

Good luck!

finance.messages.yahoo.com

=================================

"Jay Gunn 1-800-713-4046 his long term clients own over 4 million shares and they have no intention to sell until the company gets bought out.(Talk to him about the buyout price of GUMM)"

-------------------------------------------------
To:Bo Didley who wrote (7)
From: J. Gunn,Jr Friday, Jan 22, 1999 1:47 PM
View Replies (1) | Respond to of 130

Any information credited to me by bo didley or any other person or message board is inaccurate and unauthorized. I have made no previous postings regarding any stock and I will make no future postings.
J. Gunn

===============================

BO DOES KNOW DIDDLY-> "GunnAllen Financial
Jay Gunn 1-800-713-4046
his long term clients own over 4 million shares
and they have no intention to sell until the company gets bought out.
(Talk to him about the buyout price of GUMM)
bo"

To:Howard D. Epstein, M.D. who wrote (6)
From: Bo Didley Thursday, Jan 21, 1999 1:42 PM
View Replies (3) | Respond to of 130

GUMM --- STRONG BUY RATING -- $24
We are reiterating our Buy rating on GumTech International with a FY 1999 price objective of $24. This price objective is based on sales estimates of $23.5 million and $56.1 million for FY1999 and FY2000, respectively. Based on our sales estimates, GumTech could post per share earnings of $.47 for FY1999 and $1.64 for FY2000.

We continue to de-emphasize Q3 and Q4 operating results, however, based on the infancy of new product lines including Breath Asure and Ranir, and to some extent the dental gum market, while maintaining a bullish longer-term outlook. Shipments of these new gums into distribution channels have commenced, and primary indications point to strong demand for both products.

We believe that Breath Asure could capture 8.9% of the $390 million dental gum market by FY2000, while Ranir could capture as much as 7.1%. During this period we are confident that at least one, if not several, branded oral care companies will be participating in the market for dental gums.

Since the FDA apparently views plaque as a disease, and any products claiming to reduce plaque are considered to be drugs, we view GumTech's sole position as a U.S. gum manufacturing facility that currently follows the Food and Drug Administration's "drug Good Manufacturing Practices" as a clear competitive advantage in the dental gum market.

Although we decline to cite a definitive time frame, GumTech should commence domestic and international distribution of nicotine (drug) containing gums, as well as further penetrate the market for diet aiding gums, by FY 2000.

GunnAllen Financial
Jay Gunn 1-800-713-4046
his long term clients own over 4 million shares
and they have no intention to sell until the company gets bought out.
(Talk to him about the buyout price of GUMM)

bo



To: DanZ who wrote (4693)10/12/2003 4:12:34 PM
From: StockDung  Respond to of 5582
 
NUCLEAR SOAP FOR DAVE LAVIGNE->David Slavny, a J.P. Turner investment banker who was a key contact for Brown at the firm, declined to comment other than to say that "three or four persons were involved in trying to raise money" for Nuclear Solutions.

Public Disclosure Program.Employing Firm: J.P. TURNER & COMPANY, L.L.C.
Firm CRD Number: 43177
Office of Employment
Address: DENVER, CO
Start Date: 09/2002
End Date: 10/2002

File for: CRD# 1251725 DAVID LEWIS LAVIGNE

Data Current as of: 05/07/2003 File for: Data Current as of: 05/07/2003
CRD# 1251725
DAVID LEWIS LAVIGNE ALL CURRENT EMPLOYMENTS No data in this category.This section provides all current employments (investment-related and non-investment related) as reported on the broker's Form U-4. It displays the name of the employing firm that employs this broker, the firm's CRD number (if applicable), the location of the office where the broker is employed, and the broker's start date.Other Business No data in this category. PREVIOUS EMPLOYMENT This section provides 10 years of an individual's employment history. If the individual is currently registered with NASD, employment history will be displayed for the previous 10 years. If the individual is not currently registered with NASD, employment history will be displayed for the 10 years prior to termination of the registration. The firm's CRD number, the office of employment address where the broker was employed, and the dates of employment will be displayed.To view information on NASD registered firms, you can click on the firm name hyperlink.If the broker was previously employed with an investment adviser, the investment adviser's name and CRD number will display. However, additional information is not available on investment advisers through the Public Disclosure Program as they are not NASD registered firms.If the broker was previously employed with a firm registered with any self-regulatory organization other than NASD (e.g., the NYSE), either the firm's name or "Other Business" will display as the Employing Firm. To obtain the firm's name when "Other Business" displays as the Employing Firm, please call the Public Disclosure Call Center Hotline number, 1-800-289-9999.A Firm CRD Number will not display for employing firms that are not NASD registered firms. Information on these employing firms is not available through the Public Disclosure Program.

Employing Firm: J.P. TURNER & COMPANY, L.L.C.
Firm CRD Number: 43177
Office of Employment
Address: DENVER, CO
Start Date: 09/2002
End Date: 10/2002

Employing Firm: SCHNEIDER SECURITIES, INC.
Firm CRD Number: 16434
Office of Employment
Address: DENVER, CO
Start Date: 11/2000
End Date: 09/2002

Employing Firm: GLOBAL CAPITAL SECURITIES CORPORATION
Firm CRD Number: 16184
Office of Employment
Address: ENGLEWOOD, CO
Start Date: 01/1991
End Date: 11/2000
===================================

==============================================
The story of Nuclear Solutions begins with Paul Brown, its founder, a college dropout who got a Ph.D. in physics from a non-accredited organization.

News reports show that in 1989, he was fined by the state of Idaho for lying about his education and selling unregistered securities. In 1992, Brown, without admitting or denying allegations made by the Securities and Exchange Commission, agreed to a permanent injunction baring him from violating federal securities laws. The SEC alleged that Brown had made false statements about a nuclear battery developed by another company he founded called Peripheral Systems. And then there were drug possession charges which were later dismissed.

After disappearing from the business world for almost a decade, Brown reappeared last August, founding Nuclear Solutions, a small Idaho-based nuclear waste disposal company. Soon he began looking for needed financing and got in touch with an Atlanta, Ga., brokerage called J.P. Turner & Co. LLC.

The relationship between Brown and J.P. Turner was the beginning of a chain of events that led Nuclear Solutions to the center of a federal investigation involving rogue federal agents and their alleged use of confidential information to help short sellers manipulate the stock of companies. In a May indictment, the government charged that short seller Anthony Elgindy , and co-defendants Jeffrey Royer of the FBI, Derrick Cleveland and Troy Peters used information gathered from FBI databases to extort stock from Nuclear Solutions and other companies.

But back to Nuclear Solutions.

J.P. Turner helped broker two deals under which Brown pledged millions of shares in exchange for financing, according to people close to Nuclear Solutions.

David Slavny, a J.P. Turner investment banker who was a key contact for Brown at the firm, declined to comment other than to say that "three or four persons were involved in trying to raise money" for Nuclear Solutions.

========================================

Truthseeker tp profile MTXX fraud analyst Dave Lavigne this evening. A MUST READ FOR AVID INVESTORS" "RCL Northwest Inc - broker for peripheral (800) 688-1114 Dave Lavigne"

===============================
"Dave Lavigne of RCL hinted that Talbert (ex-president of Peripheral) had
stock in more names than his own and might have been doing some insider
trading. RCL has put out a buy recommendation (I believe on several occasions but
at least once) pushing the stock. "

---------------------------------------------
from Scheider Securities CRD:"PERIPHERAL
SYSTEMS STOCK BASED ON REPRESENTATIVES THAT PERIPHERAL HAD
DEVELOPED A NUCLEAR POWERED BATTERY THAT WOULD BE HIGHLY
PROFITABLE. THEY FAILED TO DISCLOSE TO INVESTORS THAT NUCELL,
A WHOLLY- OWNED SUBSIDIARY OF PERIPHERAL, WAS THE SUBJECT OF
JUDGMENTS OBTAINED IN A LAWSUIT FILED BY THE STATE OF IDAHO IN
1988 ALLEGING FRAUD IN CONNECTION WITH THE SALE OF THE NUCELL
STOCK. COHIG TOOK OVER RCL'S SPOKANE OFFICE IN 1991 AND FAILED
TO HALT THE FRAUDULENT OFFER OF PERIPHERAL SYSTEM STOCK.
CONTACT: TIM MARTIN - 208/332-8004." Reporting Source: Regulator (Form U-6)Date Reported: 02/14/1996 Initiated By: IDAHO DEPARTMENT OF FINANCEDate initiated: 02/14/1996Docket/
Case Number: 1996-7-32Allegations: COHIG AND OTHER DEFENDANTS SOLD SECURITIES IN IDAHO WHILE
MISREPRESENTING ESSENTIAL INFORMATION ABOUT THE COMPANY WHOSE
STOCK WAS BEING SOLD AND ENGAGED IN PRACTICES WHICH OPERATED
AS A FRAUD OR DECEIT UPON THEIR IDAHO CUSTOMERS. Current Status: FinalResolution: OrderResolution Date: 02/14/1996Sanctions
Ordered: Disgorgement/RestitutionResolution
Details: COHIG AGREED TO AN ADMINISTRATIVE ORDER WHICH REQUIRES COHIG TO
PROVIDE RESTITUTION TO SIX IDAHO RESIDENTS FOR PURCHASES OF
PERIPHERAL SYSTEMS, INC. STOCK.
-----------------------------------------
from dave's crdNASD Registered Person: DAVID LEWIS LAVIGNE CRD Number: 1251725
** This individual's registration with the NASD was terminated as of 10/24/2002.
Disclosure information on terminated individuals may occasionally be reported to
and captured by NASD; however, such disclosure information has not been
reviewed by the individual, and there is no regulatory requirement that
terminated individuals report any information to NASD. ** =============================================

Summary: RCL NORTHWEST AND ITS REPRESENTATIVES, GORDON WESLEY SODORFF,
JERRY RAY LINEHAN AND THEIR SUPERVISOR MICHAEL B. LAVIGNE,
INDUCED IDAHO INVESTORS TO PURCHASE SHARES OF PERIPHERAL
SYSTEMS STOCK BASED ON REPRESENTATIVES THAT PERIPHERAL HAD
DEVELOPED A NUCLEAR POWERED BATTERY THAT WOULD BE HIGHLY
PROFITABLE. THEY FAILED TO DISCLOSE TO INVESTORS THAT NUCELL,
A WHOLLY- OWNED SUBSIDIARY OF PERIPHERAL, WAS THE SUBJECT OF
JUDGMENTS OBTAINED IN A LAWSUIT FILED BY THE STATE OF IDAHO IN
1988 ALLEGING FRAUD IN CONNECTION WITH THE SALE OF THE NUCELL
STOCK. COHIG TOOK OVER RCL'S SPOKANE OFFICE IN 1991 AND FAILED
TO HALT THE FRAUDULENT OFFER OF PERIPHERAL SYSTEM STOCK.
CONTACT: TIM MARTIN - 208/332-8004.
========================================================From: Vincent Cate (vac@sam.cs.cmu.edu)
Subject: Cold Nuclear Fission / Peripheral Systems
View: Complete Thread (11 articles)
Original Format
Newsgroups: sci.physics, sci.energy, sci.physics.fusion, sci.environment, sci.skeptic
Date: 1990-08-30 11:30:36 PST There is an inventor (Paul Brown) and a company (Peripheral Systems)
that are making unbelievable claims about large quantities of electricity
being produced directly from small amounts of radioactive materials.
Since this bypasses the heat stage used in nuclear power plants or
RTGs and can not be nearly as good as they have claimed I think that
"Cold Nuclear Fission" is the correct name for it. I believe that
Peripheral Systems in general and Paul Brown in particular are making
fraudulent claims. These claims make their nuclear battery appear far
better than it can possibly be and make me wonder if they have even
built working batteries.The numbers they give out would indicate that they are getting more
electrical power out of radioactive materials than is available in the
radiation from them. For example, the radiation from Strontium-90 is
about 2.3 watts per gram (not all of this is usable). In their annual
report Peripheral has claimed they could get 70 watts from 1 gram of Sr-90.
They have also said they could get 70 watts from 1.5 curie (1/100 gram)
of Strontium-90. Another time Brown led a reporter to write that 1/100
of a gram could run an electric heater. It is impossible to produce
70 watts of electricity from 2.3 watts of radiation so these claims and
others they have made are false and make their battery sound fantastic to
investors. Misleading investors is securities fraud and against the law. Steelhawk hired Pickard Lowe and Garrick to check out the "ionic battery"
(not the RNB for which bogus claims have been made). Steelhawk started
talking with PLG in December and had an agreement in Feb 1990. The ionic
battery is a DC device that is about the same as a Burke cell (see patent
3,409,820 by Burke) except that it feeds back some of the electricity it
produces to maintain an electric field instead of using a separate battery
for the field. Brown seems to think that this is different enough to get
a patent and given our patent office he is probably right. PLG has given
Steelhawk a report that said that the ionic battery looks legitimate (not
exactly public but Steelhawk will give out the intro and the conclusion).
From this peripheral systems has come out with press releases using quotes
from PLG's report on the ionic cell and claims this report refutes
scientific and press claims that the ionic cell contradicts the laws of
thermodynamics. However, it does no such thing. The scientific and press
claims were about the RNB and, more to the point, about the amount of
electricity produced per amount of fuel.Checking around (Peripheral, SteelHawk and PLG) it seems PLG has not been
involved with the RNB in any way. Nobody at PLG has ever seen an RNB.
RNB stands for Resonant Nuclear Battery.Brown is quoted in Aerospace and Defense as saying, "Independent and
Peripheral-sponsored tests indicate that we are getting more than 25%
conversion efficiency." When I talked with Brown he said that he was
misquoted and there has been no independent verification of this. Since
they first filed on the RNB in 1986 this seems odd. Since they have had a
patent (#4,835,433) since May 1989 and are giving talks about how it works
and showing pictures of the device it seems very odd to not be willing to
show the device in action. Brown told Claire Poole of Forbes that previous claims in the press were
misquotes (seems there was some newspaper article) when she talked with
him in 1989. Then he told her that he got 70 watts from 1.5 curie of
radioactive material (see Forbes article). He told me that he did not
know where she got that number. Now their 1989 annual report (the 1990
one is not out yet) has claimed 70 watts from 1 gram of strontium-90 (140
curies). This still turns out to be bogus. When asked Brown will not say
how many grams of what material it really took to get 70 watts. It seemed
that he did not know.Since radioactive materials are not cheap, being off by another factor of
100 makes a big difference in the potential market size. For example
Brown has claimed (December 1989 Hazmat World) that they will be able to
sell devices for $1/watt of power (for example a 50,000 watt device would
cost $50,000). However with the prices I got from Brown (10 cents/curie
-- so $14/gram for Sr-90), at 25% efficiency it is on the order of
$100/watt just for strontium-90 fuel. Regular nuclear power plants are
around $2/watt, so the difference between $1/watt and $100/watt is really
drastic. At $1/watt there would be a multi-billion dollar market and at
$100/watt or more there would be a far more limited market. Brown told me
that the ionic cell will be about $5,000. It is not clear exactly how
much power this will produce. In Brown's paper presented at the the June
1990 American Nuclear Society conference he claims 0.01 to 5 watts. So at
best it is $1,000/watt and it might be as bad as $500,000/watt. Brown claimed that the military wanted to buy 10,000 of these $5,000
devices every month. Since nobody even seems sure how much power the
battery is going to produce this must not be anything close to a firm
order but the way he said it it sounded like it was. The old president (Talbert) was either fired or asked to resign recently.
Part of the reason seems to be the way he has been passing out incorrect
information. Brown says that Peripheral will not be making any more press
releases or passing out news articles like they did in the past. In my
opinion it has been very wrong to pass out news articles that had errors.
For example, one in WARD'S Engine Update says that the PLG report says
"the energy balance of the RNB is perfect and does not contradict the laws
of thermodynamics." when what the report really says has "ionic" and not
"RNB" in that sentence. The above may be due to an error by a reporter
but my guess is that most of the reporters got the quotes right (they tape
interviews) and that Brown really said most all of these errors. The problem with the amount of energy per gram of radioactive material
implied by the 1989 Peripheral Systems Annual Report is on page 4. It
says that 70 watts of electricity was produced from 1 gram of strontium-90
and 50,000 watts from 2 lbs of stuff (55 watts/gram). This is far above
the amount of energy available in the radiation. Here are my calculations
which have been checked by 3 different Nuclear engineers (two point out
that I should really use only 0.535 Mev/decay since the energy in a
neutrino can not be used, but even with this generosity Brown is way off):Specific activity of Sr-90: 139 curies/gram
Curie: 3.7e10 decays/sec
Max energy per decay: 2.8 MeV/decay
Energy equality: 1 MeV = 1.6e-13 joules
Power: 1 joule/sec = 1 wattA good source for the above is "CRC - Handbook for Radioactive Nuclides"Using the above:curie decay/sec MeV joule watt
1 gram * 139 ----- * 3.7e10--------- * 2.8 ---- * 1.6e-13 ----- * 1 ----
gram curie decay MeV j/secWe get that one gram of Sr-90 produces: 2.3 watts of radiationSo with 100% efficiency in converting to electricity the most you could
get would be 2.3 watts of electricity per gram. Numbers in the annual
report imply 70 watts of electricity is produced per gram of strontium-90.
Given the energy in the radiation and the reported efficiency of 25% it
should take about 100 times as much fuel as they are claiming. Given that
not all of the 2.8 MeV is usable, they are really off by about a factor of
500.Brown agrees with my numbers and admits that the annual report is wrong.
Brown told me that he did not write the annual report and that a marketing
or public relations person got these numbers from an incorrect newspaper
article and put them in the annual report. He also says he never noticed
this error before. Since there is only about one page of the report that
is about the nuclear battery, and it has his picture, I don't see how he
could have missed it for over a year. It makes a big deal out of how much
power can be produced from such a little amount of fuel, and even compares
this to the amount of amount of fuel used in other devices. If he had
done the experiments he claims to have then he should have known that it
took over 100 times as much fuel as the annual report said. This type of
error should have jumped out at him. My guess is that he really wrote it
or at least provided the numbers.In a London Times article Brown has led the reporter to write that "A
battery with the power output of a single bar electric fire will contain
just 1/100 of a gram of strontium-90." A "single bar electric fire" is a
small space heater, around 500 to 1,000 watts. Again, with 1 gram of
strontium-90 you can not get more than 2.3 watts, so these numbers are
really bogus.In Hazmat World (who seems to have interviewed Brown) they say that
Peripheral got 70 watts of electricity off of 1 ounce of radioactive
material. If this is strontium-90 then this is another bogus claim. I
have never seen a claim for the 70 watt device that seemed close to
reality (like, say 500 grams of strontium-90).Wayne Klein of the Idaho Securities Exchange says that securities fraud
charges were brought against Nucell and they were convicted. After this
Nucell claimed the SE drove jobs out of Idaho and Nucell left.Klein said Nucell was making all of these claims about nuclear batteries
but turned out not to even have a permit for radioactive materials. I
really doubt that you can buy the quantities of fuel needed to radiate
50,000 watts from normal decay without a permit (if it were U-235 this
would be more than enough to make a nuclear bomb). If it were so easy to
get fuel I think kids and terrorists would be building nuclear bombs,
since the only hard part is getting the fuel. I am not sure when Brown
claims to have done the 50,000 watt device, it may have been after leaving
Idaho. Even with a permit this would be a lot of fuel.Klein also said something about Brown making false claims about his
education.Dave Lavigne of RCL hinted that Talbert (ex-president of Peripheral) had
stock in more names than his own and might have been doing some insider
trading. RCL has put out a buy recommendation (I believe on several occasions but
at least once) pushing the stock. Peripheral also sold licensing rights to First Northwest Capital Inc. for
a very low price. FNCI bought $100,000 of Peripheral stock and paid
another $100,000 outright. This seems incredibly low given either the
amount that peripheral has invested or the amount it should be worth if
real (if 25% efficient etc).It also seems odd that a startup that is short on cash and needs the cash
it has to develop an amazing new product would be buying all sorts of
other companies (Peak Beam Systems Inc, PENCO, X-Ray Inc, and TriSys).Another Brown quote (seems to be misleading investors by alot) this one
from Hazmat World December 1989 page 24 (second page of article): ``"The
actual applications are unlimited," Brown suggests. "If or when we get
this to a fully developed product, the implications are tremendous. We're
talking about a low-cost, compact device that could be beneficial anywhere
power is needed. For pennies a day, you could flood the desert, or drive
an electric car until the wheels fell off. It could change the energy
industry as we know it."''Given the prices of radioactive materials and the real amount needed to
run Brown's batteries the above statement is unreasonable. I have not
really checked prices but radioactive material is not cheap.Another quote from the San Jose Mercury News, ``The cost of such a battery
will be competitive with other power sources, Talbert said. "There's
really no expensive components in it," he said.'' Radioactive material is
expensive in the quantities really needed. It does not seem to be even
near price competitive (off by a factor of 100).In Business Week they say "Brown predicts the battery will generate
electricity for 3 cents per kilowatt-hour, which is more than competitive
with conventional sources." Also it says that Talbert "thinks the battery
could supplement - or even supplant - nuclear reactors and coal-fired
generators." Given the real amounts of fuel needed they are not close to
being economically competitive.In Insight they report that at Oak Ridge people used 8,000 grams to
produce 500 watts giving 0.063 watts per gram of strontium-90. Then "The
Nucell prototype is said to yield 7,500 watts per gram of strontium-90; it
required only about 1 centigram of the isotope." This is just not real.
As the included calculations show there is at the very most 2.3 watts of
energy radiated per gram of strontium-90. Claims of 7,500 watts/gram are
false.I talked with Brown on 7/28 and 7/29 at the International Tesla Symposium.
At this time he told me that the 50 kw device they built ran for 15
minutes, the 70 watt device ran for 3 weeks and the 5 watt device ran for
months untouched. I have reason to believe that the 5 watt device does
not yet exist. I have the strongest of doubts about the 50 kw device. I
am sure that 1 gram of Sr-90 is not enough to produce 70 watts. Just in
case you are impressed by Brown giving a talk at this conference let me
tell you that it was organized by a relator in Colorado Springs (Mr
McInnis (719) 576-1985) and the "scientist" talking before Brown believed
that the future could affect the past and her experimental results were
that a computer crashed once. This was a very bogus conference.Several physicists that I know have pointed out that even real physics
conferences will let anyone speak. This is in strong contrast to
conferences in many other fields.I know a physicist who corresponded with Brown about errors in Brown's
calculations around 2 years ago. It seems Brown had made some mistakes
and was under a very mistaken impression about how many watts of radiation
were put off per gram of fuel. My guess is that from these mistaken
calculations he made up his "experimental results". This physicist mailed
copies of his letters to Brown to me (they are not here yet) and said that
I could tell people about the letters from Brown. He was not sure he
should give me copies of Brown's letters (possible problem with copyright
and/or non-disclosure) but said a subpena for the documents would make it
possible for him to give them out.Ewart Blackman told me something I found interesting. Brown got one of
his power output numbers by calculating how many watts it must have taken
to burn out a wire that blew one time (like how many watts for 1/10 second
to blow a wire). The clear problem with this is that there is a lot of
energy stored in the capacitor and inductor so it could output a high
wattage for a short time without producing any energy at all. So this
burst of energy is a really bogus way to come up with numbers for energy
production.Two more bogus claims are in the patent. This is particularly strong
because it (like the annual report) is straight from them. They claim to
have gotten 9,000 watts off of the following combination: 1 milicurie of
radium, 200 grams of uranium, 100 grams of thorium. They claim that
there is a synergistic effect between the radioactive materials and that
more power can be obtained by adding a second milicurie of radium. The
synergistic effect stuff is bogus. It takes a lot of energy to cause an
atom to split (like a gamma-ray) and given the amount of material (well
under a critical mass) there could not have been much of this going on.
Brown refused to tell me which isotope of uranium and thorium he used but
even if the uranium were U-235 (instead of the common U-238) the
watts/gram would still be many orders of magnitude off. PHONE NUMBERS:Peripheral Systems and Nucell (800) 468-8215
Pickard, Lowe and Garrick (714) 650-8000 Stan Kaplan
Peripheral Systems FAX number (303) 624-8526
Steelhawk Resources Ltd 1-800-565-9990 Mike Cartmell
RCL Northwest Inc - broker for peripheral (800) 688-1114 Dave Lavigne
Forbes magazine (713) 228-2272 Claire Poole
Triumf - Ewart Blackmore - (604) 222-1047
Oregon Securities Exchange (503) 378-4387
Idaho Securities Exchange (208) 334-3684 - Wayne Klein
Seattle Securities Exchange Commission (206) 442-7990 Derel HegalARTICLES:Peripheral Systems Annual Report May 1989
Tesla Technology and Radioisotopic Energy Generation - Brown July 1990
Peripheral RNB Patent #4,835,433
The Beta Voltaic Effect ... - Brown June 1990
RCL Northwest Inc Buy recommendation 2/28/90
San Jose Mercury News, August 12, 1989, Page 9A. - * from mother
Peripheral Systems "Dear Shareholder" of May 18 1990
Peripheral Systems Inc correction press release - * through PLG
Soup-can Physics - Forbes March 6 1989 p 142 - * from CMU library
Financial Markets - Vol 1 No 6, May 1990
Investors Eye New Battery Technology - Today's Investor May 11 1990
Multiple Uses Seen for Improved Battery - IPN May/June 1990
WARD'S Engine Update July 1, 1990, page 5
Researchers harness energy from nuclear waste - Hazmat World Dec 1989
Crisis Investing - The Robb Report - June 1990
International Tesla Symposium handout - July 1990
Nuclear battery mops up waste - The Sunday Times - LONDON - Nov 12, 1989
A Pint-size Power Source Packing an Atomic Punch - Bus Week Aug 29 1988
Nuclear Battery Taps Fission By-product - Insight - Aug 29 1988
Steelhawk press release of May 10 1990
Steelhawk press release of June 13 1990
Steelhawk press release of Feb 1 1990
Note from Mike Cartmell
Intro and Conclusion of PLG Ionic Battery report
PLG description and Kaplan Johnson Bley descriptionBurke Patent #3,409,820I know a few more things that I have told a few people I would not give
out (they may have just been afraid of me giving it to the press). Most
of it is not good for Brown or Peripheral. If there were a court case I
could come up with some more things.Brown has been quoted with many bogus numbers for battery power and
quantity of radioactive material. When confronted and asked for the real
numbers he agreed that reported numbers were wrong but that the real
numbers were proprietary. It is as if he is willing to give out bogus
numbers to the press and print bogus numbers in the annual report but he
keeps the real numbers top secret.The RNB may or may not actually produce some electricity but Brown's
claims make it look far better than it can possibly be. I am surprised
that he has not been charged with securities fraud since leaving Idaho.If there are any reporters reading this who would like to do a story
please give me a call. If you know a reporter who might be interested
feel free to forward this to them. If you know someone who has invested
in this company they might appreciate your telling them the above.-- VinceName: Vincent Cate
Email: vac@cs.cmu.edu
Home Phone: (412) 361-1447
Work Phone: (412) 268-3077
FAX: (412) 681-1998Address: 6938 Meade St, Apt 2
Pittsburgh PA, 15208



To: DanZ who wrote (4693)10/12/2003 10:40:25 PM
From: StockDung  Respond to of 5582
 
Shows that forcing and hyping a short squeeze is actually manipulation. When is MTXX adding you to their law suit Dan Zimmermann for market manipulation!!

sec.gov

sec.gov

sec.gov



To: DanZ who wrote (4693)10/13/2003 12:21:07 PM
From: StockDung  Respond to of 5582
 
SEC GETS TOUGH: As an example of the new SEC attitude, the insider pointed out that during a recent meeting of the SEC's enforcement division, Stephen Cutler, the division chief, ordered staff to thoroughly comb through financial industry trade journals.

The purpose? Cutler wanted to find questionable practices the SEC may be ignoring or unaware of. "That desire to be proactive comes down from Donaldson," the insider said.

nypost.com



To: DanZ who wrote (4693)10/13/2003 8:00:11 PM
From: StockDung  Respond to of 5582
 
Boy is this board quiet all of a sudden
by: lanman1_99 (33/M/Chicago, IL)
Long-Term Sentiment: Buy 10/13/03 07:45 pm
Msg: 83823 of 83824

Floyd, I hope they lock you up and throw away the key...best of luck in the slammer, shithead...